Withdrawal: Makena
Apr. 2023Pharmacy Updates
On March 7, 2023, Covis Pharma announced that it is withdrawing Makena (hydroxyprogesterone caproate injection; also referred to as 17-OHPC) from the market. This drug is used to reduce the risk of preterm birth in women who are pregnant with one baby and have a history of spontaneous preterm birth. Read more about the Makena withdrawal.
Recent Announcements
Understanding MP.PA.147
Understanding changes to the Diagnostic and Surveillance Colonoscopy, 18 Years Old and Older – MP.PA.147 policyJul. 2025Important Notices
Understanding MP.PA.147
Understanding changes to the Diagnostic and Surveillance Colonoscopy, 18 Years Old and Older – MP.PA.147 policyJul. 2025Important Notices
Register for the Oral Health in Your Pediatric Office CME -accredited webinar
Please join us for a live, CME-accredited webinar on Wednesday, Sept. 10 from noon to 1 p.m. that will provide an overview of oral health in your pediatric office. Providers with a(n) MD/DO, PA, CRNP, RN, or LPN may also apply for topical fluoride certification after completion of this course.Jun. 2025Education/Webinars